middle.news
Paradigm Biopharma Draws US$3 Million to Support Phase 3 Osteoarthritis Trial
1:14pm on Monday 13th of July, 2026 AEST
•
Healthcare
Read Story
Paradigm Biopharma Draws US$3 Million to Support Phase 3 Osteoarthritis Trial
1:14pm on Monday 13th of July, 2026 AEST
Key Points
US$3 million drawdown completed under Convertible Note Facility
Supports ongoing Phase 3 PARA_OA_012 trial with 538 participants enrolled
Approximately US$7 million remains available for trial and commercial activities
Funding aligned with interim analysis and primary endpoint readout milestones
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE